MX2022003628A - Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. - Google Patents

Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.

Info

Publication number
MX2022003628A
MX2022003628A MX2022003628A MX2022003628A MX2022003628A MX 2022003628 A MX2022003628 A MX 2022003628A MX 2022003628 A MX2022003628 A MX 2022003628A MX 2022003628 A MX2022003628 A MX 2022003628A MX 2022003628 A MX2022003628 A MX 2022003628A
Authority
MX
Mexico
Prior art keywords
treatment
cell carcinoma
squamous cell
patients
locally advanced
Prior art date
Application number
MX2022003628A
Other languages
English (en)
Spanish (es)
Inventor
Claudio Zanna
Silvano Brienza
Altman Sergio Adrian Szyldergemajn
Jean Bourhis
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of MX2022003628A publication Critical patent/MX2022003628A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022003628A 2019-09-25 2020-09-25 Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. MX2022003628A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962905703P 2019-09-25 2019-09-25
US202063016762P 2020-04-28 2020-04-28
EP20184601 2020-07-07
PCT/EP2020/076994 WO2021058794A1 (en) 2019-09-25 2020-09-25 Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma

Publications (1)

Publication Number Publication Date
MX2022003628A true MX2022003628A (es) 2022-07-21

Family

ID=72644266

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003628A MX2022003628A (es) 2019-09-25 2020-09-25 Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.

Country Status (13)

Country Link
US (1) US20250268863A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034102A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022550037A (cg-RX-API-DMAC7.html)
KR (1) KR20220088700A (cg-RX-API-DMAC7.html)
CN (1) CN114727984A (cg-RX-API-DMAC7.html)
AU (1) AU2020356356A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005624A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151770A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022004947A2 (cg-RX-API-DMAC7.html)
IL (1) IL291682A (cg-RX-API-DMAC7.html)
MX (1) MX2022003628A (cg-RX-API-DMAC7.html)
PH (1) PH12022550721A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021058794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024022275A1 (zh) * 2022-07-29 2024-02-01 苏州科睿思制药有限公司 Xevinapant的晶型及其制备方法和用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525585T3 (es) 2006-05-05 2014-12-26 The Regents Of The University Of Michigan Intermedios para la preparación de miméticos de SMAC bivalentes
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008128171A2 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
EP2296650B1 (en) 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
ES2643233T3 (es) 2009-10-23 2017-11-21 The Regents Of The University Of Michigan Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos
EP2493879B1 (en) 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患(がん)の治療において使用するためのSMAC模倣体(ビリナパント(birinapant))
US8859541B2 (en) 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
AU2013306087B2 (en) 2012-08-23 2017-08-10 The Regents Of The University Of Michigan Bivalent inhibitors of IAP proteins and therapeutic methods using the same
CA2896577C (en) 2012-11-30 2024-01-23 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
WO2014121178A1 (en) 2013-02-04 2014-08-07 Tetralogic Pharmaceuticals Corp. Smac mimetic method of treatment
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
AR101479A1 (es) 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
AU2015360095B2 (en) * 2014-12-09 2020-02-27 Advenchen Laboratories Nanjing Ltd Quinoline derivative against non-small cell lung cancer
CA2916970A1 (en) 2016-01-08 2017-07-08 Pharmascience Inc. A smac mimetic compound for use in the treatment of proliferative diseases
EP3419643A4 (en) 2016-02-24 2020-04-01 Children's Hospital of Eastern Ontario Research Institute Inc. SMC COMBINATION THERAPY FOR TREATING CANCER
CN110475567A (zh) 2017-03-31 2019-11-19 勃林格殷格翰国际有限公司 抗癌组合疗法
WO2019122941A1 (en) * 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule

Also Published As

Publication number Publication date
US20250268863A1 (en) 2025-08-28
PH12022550721A1 (en) 2024-05-13
AU2020356356A1 (en) 2022-05-12
IL291682A (en) 2022-05-01
CA3151770A1 (en) 2021-04-01
CO2022004947A2 (es) 2022-08-30
EP4034102A1 (en) 2022-08-03
CN114727984A (zh) 2022-07-08
KR20220088700A (ko) 2022-06-28
WO2021058794A1 (en) 2021-04-01
JP2022550037A (ja) 2022-11-30
BR112022005624A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
MX2024010140A (es) Nuevos metodos.
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX383499B (es) Agentes terapeuticos para enfermedades neurodegenerativas
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
BR112017000556A2 (pt) terapia de combinação para câncer
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
ECSP19075677A (es) Compuesto macrocíclico y sus usos
MX2017009122A (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2016011115A (es) Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2021007477A (es) Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer.
AR119159A1 (es) Tratamientos de angioedema